Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04208178
Title Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (EPIK-B2)
Acronym EPIK-B2
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | BEL

Facility Status City State Zip Country Details
Highlands Oncology Group Main Fayetteville Arkansas 72703 United States Details
University Of California Los Angeles Reg-5 Los Angeles California 90095 United States Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Liege 4000 Belgium Details
Novartis Investigative Site Chang Chun Jilin 130021 China Details
Novartis Investigative Site Shanghai 200032 China Details
Novartis Investigative Site Saint-Cloud Hauts De Seine 92210 France Details
Novartis Investigative Site Saint-Herblain Cédex 44805 France Details
Novartis Investigative Site Firenze FI 50134 Italy Details
Novartis Investigative Site Kuala Lumpur 59100 Malaysia Details
Novartis Investigative Site Hospitalet de LLobregat Catalunya 08907 Spain Details
Novartis Investigative Site Samsun 55200 Turkey Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field